Cargando…
Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction. METHODS AND RESULTS: We conducted a systematic rev...
Autores principales: | Toth, Peter P., Worthy, Gillian, Gandra, Shravanthi R., Sattar, Naveed, Bray, Sarah, Cheng, Lung‐I., Bridges, Ian, Worth, Gavin M., Dent, Ricardo, Forbes, Carol A., Deshpande, Sohan, Ross, Janine, Kleijnen, Jos, Stroes, Erik S. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721820/ https://www.ncbi.nlm.nih.gov/pubmed/28971955 http://dx.doi.org/10.1161/JAHA.116.005367 |
Ejemplares similares
-
Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
por: Toth, Peter P., et al.
Publicado: (2022) -
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016) -
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016) -
The relationship between Lp(a) and CVD outcomes: a systematic review
por: Forbes, Carol A., et al.
Publicado: (2016) -
Impact of hyperlipidemia and atrial fibrillation on the efficacy of endovascular treatment for acute ischemic stroke: a meta-analysis
por: Zheng, Jingwei, et al.
Publicado: (2017)